IL158412A0 - A method for increasing the compactability of an active ingredient and a process for producing a solid dosage form having a high active ingredient drug load - Google Patents
A method for increasing the compactability of an active ingredient and a process for producing a solid dosage form having a high active ingredient drug loadInfo
- Publication number
- IL158412A0 IL158412A0 IL15841202A IL15841202A IL158412A0 IL 158412 A0 IL158412 A0 IL 158412A0 IL 15841202 A IL15841202 A IL 15841202A IL 15841202 A IL15841202 A IL 15841202A IL 158412 A0 IL158412 A0 IL 158412A0
- Authority
- IL
- Israel
- Prior art keywords
- active ingredient
- compactability
- producing
- increasing
- dosage form
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000007909 solid dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28687001P | 2001-04-26 | 2001-04-26 | |
| US28668201P | 2001-04-26 | 2001-04-26 | |
| PCT/US2002/013055 WO2002088664A2 (en) | 2001-04-26 | 2002-04-23 | Control of compactability through crystallization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL158412A0 true IL158412A0 (en) | 2004-05-12 |
Family
ID=26964005
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15841202A IL158412A0 (en) | 2001-04-26 | 2002-04-23 | A method for increasing the compactability of an active ingredient and a process for producing a solid dosage form having a high active ingredient drug load |
| IL15823502A IL158235A0 (en) | 2001-04-26 | 2002-04-23 | A pharmaceutical tablet having high sulfhydryl-based matrix metalloproteinase inhibitor content |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15823502A IL158235A0 (en) | 2001-04-26 | 2002-04-23 | A pharmaceutical tablet having high sulfhydryl-based matrix metalloproteinase inhibitor content |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20040175419A1 (cs) |
| EP (2) | EP1390018A1 (cs) |
| JP (2) | JP2005505501A (cs) |
| KR (1) | KR20040036686A (cs) |
| CN (2) | CN1523981A (cs) |
| BR (2) | BR0209199A (cs) |
| CA (2) | CA2445290A1 (cs) |
| CZ (2) | CZ20032902A3 (cs) |
| HU (2) | HUP0303860A3 (cs) |
| IL (2) | IL158412A0 (cs) |
| MX (2) | MXPA03009676A (cs) |
| PL (2) | PL367262A1 (cs) |
| WO (2) | WO2002087548A1 (cs) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1243262T3 (da) | 2001-03-20 | 2006-10-02 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter |
| ES2185606T3 (es) | 2001-03-21 | 2003-05-01 | Sanol Arznei Schwarz Gmbh | Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma. |
| GB0513881D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
| GB0329667D0 (en) | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
| US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
| EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
| PL1781276T3 (pl) | 2004-08-27 | 2010-11-30 | Ucb Pharma Gmbh | Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy |
| GB0513888D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
| GB0513883D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Diagnosis of Atherosclerosis |
| WO2007144195A2 (en) | 2006-06-15 | 2007-12-21 | Schwarz Pharma Ag | Pharmaceutical composition with synergistic anticonvulsant effect |
| GB0722484D0 (en) * | 2007-11-15 | 2007-12-27 | Ucl Business Plc | Solid compositions |
| WO2011156061A1 (en) | 2010-06-07 | 2011-12-15 | Telik, Inc. | Preparation of crystalline ezatiostat hydrochloride ansolvate form d |
| EP2576591A2 (en) * | 2010-06-07 | 2013-04-10 | Telik, Inc. | Tablet formulation of ezatiostat |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4476248A (en) * | 1983-02-28 | 1984-10-09 | The Upjohn Company | Crystallization of ibuprofen |
| ES2150438T3 (es) * | 1991-12-30 | 2000-12-01 | Fmc Corp | Composicion de esferonizacion a base de celulosa microcristalina. |
| WO1997012902A1 (en) * | 1995-10-05 | 1997-04-10 | Darwin Discovery Limited | Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation |
-
2002
- 2002-04-23 CA CA002445290A patent/CA2445290A1/en not_active Abandoned
- 2002-04-23 BR BR0209199-2A patent/BR0209199A/pt unknown
- 2002-04-23 JP JP2002585919A patent/JP2005505501A/ja active Pending
- 2002-04-23 US US10/475,959 patent/US20040175419A1/en not_active Abandoned
- 2002-04-23 EP EP02723952A patent/EP1390018A1/en not_active Withdrawn
- 2002-04-23 HU HU0303860A patent/HUP0303860A3/hu unknown
- 2002-04-23 CZ CZ20032902A patent/CZ20032902A3/cs unknown
- 2002-04-23 PL PL02367262A patent/PL367262A1/xx not_active Application Discontinuation
- 2002-04-23 MX MXPA03009676A patent/MXPA03009676A/es unknown
- 2002-04-23 KR KR10-2003-7013698A patent/KR20040036686A/ko not_active Withdrawn
- 2002-04-23 WO PCT/US2002/012915 patent/WO2002087548A1/en not_active Ceased
- 2002-04-23 BR BR0209155-0A patent/BR0209155A/pt not_active Application Discontinuation
- 2002-04-23 IL IL15841202A patent/IL158412A0/xx unknown
- 2002-04-23 CN CNA028089944A patent/CN1523981A/zh active Pending
- 2002-04-23 HU HU0400377A patent/HUP0400377A2/hu unknown
- 2002-04-23 CN CNA02812779XA patent/CN1520283A/zh active Pending
- 2002-04-23 IL IL15823502A patent/IL158235A0/xx unknown
- 2002-04-23 CA CA002445702A patent/CA2445702A1/en not_active Abandoned
- 2002-04-23 WO PCT/US2002/013055 patent/WO2002088664A2/en not_active Ceased
- 2002-04-23 JP JP2002584894A patent/JP2004530679A/ja not_active Withdrawn
- 2002-04-23 MX MXPA03009689A patent/MXPA03009689A/es unknown
- 2002-04-23 US US10/476,047 patent/US20040208924A1/en not_active Abandoned
- 2002-04-23 EP EP02728982A patent/EP1390011A2/en not_active Withdrawn
- 2002-04-23 PL PL02373548A patent/PL373548A1/xx not_active Application Discontinuation
- 2002-04-23 CZ CZ20032901A patent/CZ20032901A3/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL158235A0 (en) | 2004-05-12 |
| WO2002087548A1 (en) | 2002-11-07 |
| WO2002088664A2 (en) | 2002-11-07 |
| PL367262A1 (en) | 2005-02-21 |
| KR20040036686A (ko) | 2004-04-30 |
| JP2005505501A (ja) | 2005-02-24 |
| BR0209155A (pt) | 2004-10-05 |
| CN1520283A (zh) | 2004-08-11 |
| PL373548A1 (en) | 2005-09-05 |
| MXPA03009676A (es) | 2004-02-12 |
| CN1523981A (zh) | 2004-08-25 |
| HUP0400377A2 (en) | 2007-09-28 |
| HUP0303860A3 (en) | 2005-05-30 |
| JP2004530679A (ja) | 2004-10-07 |
| CZ20032902A3 (cs) | 2004-01-14 |
| WO2002088664A3 (en) | 2003-08-21 |
| MXPA03009689A (es) | 2004-02-12 |
| CZ20032901A3 (en) | 2004-07-14 |
| US20040175419A1 (en) | 2004-09-09 |
| CA2445702A1 (en) | 2002-11-07 |
| EP1390011A2 (en) | 2004-02-25 |
| BR0209199A (pt) | 2006-02-07 |
| CA2445290A1 (en) | 2002-11-07 |
| HUP0303860A2 (hu) | 2004-03-29 |
| US20040208924A1 (en) | 2004-10-21 |
| EP1390018A1 (en) | 2004-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0003121A3 (en) | Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance | |
| HUP0204170A3 (en) | 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient | |
| HUP0301325A3 (en) | Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition | |
| SI1417206T1 (sl) | Novi H piridazin onski derivati farmacevtski sestavki ki jih vsebujejo in postopek za pripravo aktivne sestavine | |
| AU2002358270A1 (en) | Zero-order sustained released dosage forms and method of making the same | |
| HUP0303891A3 (en) | Pharmaceutically active piridine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0401963A3 (en) | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | |
| IL158412A0 (en) | A method for increasing the compactability of an active ingredient and a process for producing a solid dosage form having a high active ingredient drug load | |
| AU2002342755A1 (en) | Method and device for producing granulates that comprise at least one pharmaceutical active substance | |
| HRP20030858A2 (en) | Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency | |
| IL159217A0 (en) | An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine | |
| HUP0400155A3 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
| IL150528A0 (en) | Ibuprofen containing active agent preparation | |
| NZ515644A (en) | Oil-core compositions for the sustained release of hydrophobic drugs | |
| AU2002238855A1 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
| HUP0302050A3 (en) | Pharmaceutical form of administration for peptides, method for its production and use | |
| SG116507A1 (en) | Pharmaceutical dosage form and method of making. | |
| AU2002234545A1 (en) | Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient | |
| IL161983A0 (en) | Preparation compositions containing acid-unstable physiologically active compounds, and process for producing the same | |
| WO2005004860A3 (fr) | Nouvelle composition pharmaceutique solide comprenant de l'amisulpride | |
| AU2003302188A8 (en) | Method of obtaining a soothing active ingredient, active ingredient and compositions obtained | |
| CA2495527A1 (en) | New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof | |
| HUP0203443A3 (en) | Novel contraceptive medicament and method for producing the same | |
| ZA200303276B (en) | Stable pharmaceutical form of an anticancer drug and method for production of stable pharmaceutical form of an anticancer drug. | |
| AU2001282071A1 (en) | Multiparticulate pharmaceutical dosage form and a method for producing the same |